Provectus Biopharmaceuticals, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 31.48 | -100% | 0 | 0% |
| P/S |
|
0 | 3.24 | -100% |
|
|
| P/BV |
|
-5.25 | 3.36 | -256.2% |
|
|
| P/FCF |
|
0 | 21.26 | -100% |
|
|
| Ev/Ebitda |
|
-15.13 | 9.95 | -251.95% |
|
|
| Ev/S |
|
0 | 1.89 | -100% |
|
|
| Ev/FCF |
|
-16.61 | 19.96 | -183.24% |
|
|
| E/P |
|
0 | 1.47 | -100% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
0 | 24.35 | -100% | 0 | 0% |
| ROE |
|
40.85 | 13.19 | 209.68% |
|
|
| ROA |
|
-214.09 | 6.14 | -3588.29% |
|
|
| ROIC |
|
0 | 15.56 | -100% |
|
|
| ROS |
|
0 | 12.56 | -100% |
|
|
| ROCE |
|
0 | 14.36 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
0 | 6.21 | -100% | -1.28 | -100% |
| Nеt Debt/Ebitda |
|
-0.846 | -5.72 | -85.22% |
|
|
| Debt/Ratio |
|
0 | 0.2122 | -100% |
|
|
| Debt/Equity |
|
0 | 12.49 | -100% |
|
|
| Debt/Net Income |
|
0 | 15.05 | -100% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 1.76 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 1.21 | -100% | ||
| DSI |
|
0 | 0.7783 | -100% |
|
|
| Average dividend growth |
|
0 | -269.81 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 2.8 | -100% |
|
|
| Average percentage for payments |
|
0 | 246.79 | -100% |
|
|
| Difference from average difference in sector |
|
-1.76 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
0/10
|
-96.88 | 140.59 | -168.91% | ||
| Growth impulse Ebitda in 5 years |
|
-48 | 107.17 | -144.79% | ||
| Growth impulse Net Income in 5 years |
|
-55.05 | 123.16 | -144.7% | ||
| Growth impulse FCF in 5 years |
|
-58.52 | 93.68 | -162.47% | ||
| Growth impulse EPS in 5 years |
|
-58.46 | 229.02 | -125.53% |
IP Score
2.68/10
